We are live on
!
Find out more
EAM
Eventide Asset Management Portfolio holdings
AUM
$6.05B
1-Year Est. Return
76.64%
This Fund
S&P 500
This Quarter
Est. Return
+11.85%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.51B
AUM Growth
-$26.5M
(-1.7%)
Cap. Flow
-$152M
Cap. Flow
% of AUM
-10.08%
Top 10 Holdings %
Top 10 Hldgs %
28.6%
Holding
136
New
8
Increased
26
Reduced
33
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Twilio
TWLO
|
+$20.1M |
| 2 |
Wayfair
W
|
+$13.8M |
| 3 |
Vulcan Materials
VMC
|
+$13.5M |
| 4 |
AIMT
Aimmune Therapeutics
AIMT
|
+$6.36M |
| 5 |
XLRN
Acceleron Pharma
XLRN
|
+$5.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MBLY
Mobileye N.V.
MBLY
|
+$33.3M |
| 2 |
Lear
LEA
|
+$23.6M |
| 3 |
AbbVie
ABBV
|
+$17.9M |
| 4 |
ATHN
Athenahealth, Inc.
ATHN
|
+$17.5M |
| 5 |
BorgWarner
BWA
|
+$17.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.11% |
| 2 | Consumer Discretionary | 15.23% |
| 3 | Technology | 14.9% |
| 4 | Industrials | 11.42% |
| 5 | Utilities | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Norfolk Southern
NSC
$75B
| – | – |
-2,700
| Closed | -$292K |
|
127
Novavax
NVAX
$1.22B
| – | – |
-72,485
| Closed | -$1.83M |
|
128
TG Therapeutics
TGTX
$8.19B
| – | – |
-537,600
| Closed | -$2.5M |
|
129
Tandem Diabetes Care
TNDM
$1.3B
| – | – |
-27,500
| Closed | -$591K |
|
130
Wabtec
WAB
$49.4B
| – | – |
-160,000
| Closed | -$13.3M |
|
|
ZSAN
131
DELISTED
Zosano Pharma Corporation
ZSAN
| – | – |
-389
| Closed | -$212K |
|
|
CSLT
132
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| – | – |
-1,170,000
| Closed | -$5.79M |
|
|
APU
133
DELISTED
AmeriGas Partners, L.P.
APU
| – | – |
-12,900
| Closed | -$618K |
|
|
MBLY
134
DELISTED
Mobileye N.V.
MBLY
| – | – |
-873,800
| Closed | -$33.3M |
|
|
CPPL
135
DELISTED
Columbia Pipeline Partners LP
CPPL
| – | – |
-45,000
| Closed | -$772K |
|
|
OMED
136
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| – | – |
-190,000
| Closed | -$1.47M |
|
Similar funds
HPG
EMPI
RCG
JWBC
AAM
AA
CM
CIS
Eventide Asset Management's Q1 2017 Portfolio in Review
As of Q1 2017, Eventide Asset Management held 136 positions worth $1.51B, down 1.7% from $1.54B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Eventide Asset Management withdrew a net $152M in Q1 2017, closing 15 positions and reducing 33 holdings. Its most notable exit was Mobileye N.V., an estimated $33.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 33% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, Eventide Asset Management opened a new position in Twilio worth $19.2M.
- Eventide Asset Management's largest Q1 2017 buy was Twilio: 665,000 shares worth $19.2M.
- Eventide Asset Management added most to Wayfair in Q1 2017, an estimated $13.8M increase.
- Eventide Asset Management's biggest Q1 2017 reduction was Lear, cutting an estimated $23.6M.
- Eventide Asset Management fully exited Mobileye N.V. in Q1 2017, selling an estimated $33.3M.
- Eventide Asset Management's ten largest holdings make up 29% of its $1.51B portfolio in Q1 2017.
- Eventide Asset Management opened 8 new positions and closed 15 in Q1 2017.
- Eventide Asset Management's portfolio value fell 1.7% quarter-over-quarter to $1.51B.
Based on Eventide Asset Management's 13F filing for Q1 2017, filed 15 May 2017.